LY4086940

LY4086940 is an investigational drug being developed by Eli Lilly and Company for the treatment of obesity and overweight, and is also being studied in individuals with or without type 2 diabetes. The main focus of current clinical research is to evaluate its safety, tolerability, and pharmacokinetics in healthy participants and those with overweight or obesity, including some with type 2 diabetes[3][7][9]. LY4086940 is classified as a new molecular entity and is considered unique due to its potential to target specific genetic or metabolic pathways involved in obesity, rather than only suppressing appetite or nutrient absorption, possibly enabling more personalized therapy[1]. As of now, the precise mechanism of action has not been disclosed and remains undefined in public sources[7]. All known studies to date have used oral administration in early-phase clinical trials.